BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.1B
1-Year Est. Return
139.98%
This Fund
S&P 500
1 Year Est. Return
+139.98%
AUM
$17.1B
AUM Growth
+$3.24B
(+23%)
Holding
100
Top Buys
| 1 | +$135M | |
| 2 | +$92.2M | |
| 3 | +$81.4M | |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$60.9M |
| 5 |
Alkermes
ALKS
|
+$57.5M |
Top Sells
| 1 | +$54.1M | |
| 2 | +$47.4M | |
| 3 | +$39M | |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$27.2M |
| 5 |
Vaxcyte
PCVX
|
+$23.1M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$20.2B
| $3.04B | 17.78% |
30,743,991
+328
|
|
||
|
ONC
2
BeOne Medicines Ltd
ONC
$35.1B
| $2.67B | 15.65% |
8,799,053
|
|
||
3
Madrigal Pharmaceuticals
MDGL
$9.81B
| $1.25B | 7.3% |
2,141,701
|
|
||
4
Insmed
INSM
$31.8B
| $1.15B | 6.72% |
6,592,746
-110,738
|
|
||
5
Acadia Pharmaceuticals
ACAD
$4.16B
| $1.15B | 6.71% |
42,896,690
|
|
||
6
Celcuity
CELC
$5.17B
| $790M | 4.62% |
7,915,792
|
|
||
7
Revolution Medicines
RVMD
$19.7B
| $753M | 4.41% |
9,455,357
|
|
||
8
Kymera Therapeutics
KYMR
$7.31B
| $674M | 3.94% |
8,657,242
+2,005,813
|
|
||
9
Summit Therapeutics
SMMT
$12.4B
| $636M | 3.73% |
36,391,063
+2,668,089
|
|
||
10
Rhythm Pharmaceuticals
RYTM
$6.19B
| $600M | 3.51% |
5,604,483
|
|
||
11
Kodiak Sciences
KOD
$1.64B
| $557M | 3.26% |
19,919,186
+2,608,696
|
|
||
12
Praxis Precision Medicines
PRAX
$9.34B
| $332M | 1.94% |
1,126,488
+437,000
|
|
||
|
13
Alkermes
ALKS
$4.97B
| $280M | 1.64% |
10,012,267
+1,920,916
|
|
||
|
GRAL
14
GRAIL Inc
GRAL
$2.08B
| $178M | 1.05% |
2,085,333
+455,208
|
|
||
15
Edgewise Therapeutics
EWTX
$3.22B
| $163M | 0.96% |
6,575,940
-730,000
|
|
||
16
Arrowhead Research
ARWR
$8.86B
| $144M | 0.85% |
2,175,645
+504,883
|
|
||
17
Ionis Pharmaceuticals
IONS
$13.1B
| $142M | 0.83% |
1,791,841
+1,225,043
|
|
||
18
Immunovant
IMVT
$5.64B
| $139M | 0.81% |
5,457,881
|
|
||
19
Immatics
IMTX
$1.39B
| $127M | 0.74% |
12,094,094
|
|
||
20
IDEAYA Biosciences
IDYA
$2.83B
| $125M | 0.73% |
3,618,826
+343,382
|
|
||
21
Roivant Sciences
ROIV
$20.7B
| $121M | 0.71% |
5,555,017
+1,787,244
|
|
||
|
ABVX
22
Abivax
ABVX
$9.59B
| $118M | 0.69% |
875,796
|
|
||
23
Kiniksa Pharmaceuticals
KNSA
$3.37B
| $117M | 0.68% |
2,826,246
+1,577
|
|
||
24
Replimune Group
REPL
$632M
| $107M | 0.63% |
11,045,336
|
|
||
25
Stoke Therapeutics
STOK
$2.08B
| $106M | 0.62% |
3,336,697
-1,297,141
|
|